-
About UsBPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
-
S&TInternational-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
-
Research and DevelopmentChina has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
-
BlogIntegrating industry-related media coverage as well as the company’s various activities and updates.
-
Join UsBoasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
-
![[Case Study] Issue 340: Nilotinib Plus Induction Chemotherapy Followed by Concurrent Chemo-Radiotherapy and Maintenance Therapy for Locally Advanced Nasopharyngeal Cancer](https://omo-oss-image.thefastimg.com/portal-saas/pg2025110509253779069/cms/image/327669a1-18e7-466c-a2bb-c9838fe0f7c6.jpg "[Case Study] Issue 340: Nilotinib Plus Induction Chemotherapy Followed by Concurrent Chemo-Radiotherapy and Maintenance Therapy for Locally Advanced Nasopharyngeal Cancer")
Biotech pharmaceutical co., Ltd
Email: cooperation@biotechplc.com
BD Dept: bd@biotechplc.com
Address：NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176
Biotech pharmaceutical co., Ltd
中企跨境-全域组件 1.92
制作前进入CSS配置样式
E-mail：
Tel：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： BIOTECH PHARMACEUTICAL CO., LTD
表单验证提示文本： Content cannot be empty!
循环体没有内容时： Sorry, no matching items were found.
CSS / JS 文件放置地